Cladribine (2-chlorodeoxyadenosine)
- 1 October 1992
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 340 (8825) , 952-956
- https://doi.org/10.1016/0140-6736(92)92826-2
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Response to 2-Chlorodeoxyadenosine in Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to FludarabineNew England Journal of Medicine, 1992
- Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.Proceedings of the National Academy of Sciences, 1992
- 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1991
- 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive NucleosideLeukemia & Lymphoma, 1991
- Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.Journal of Clinical Investigation, 1990
- Purine metabolism as a target for leukemia chemotherapyBlood Reviews, 1989
- DNA strand breaks, NAD metabolism, and programmed cell deathExperimental Cell Research, 1986
- Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.Journal of Clinical Investigation, 1985
- Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.Proceedings of the National Academy of Sciences, 1984
- Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)Proceedings of the National Academy of Sciences, 1977